HC Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail By Investing.com – Investing.com
- Date: 29-Dec-2021
- Source: Investing.com
- Sector:Healthcare
- Country:Middle East
HC Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail By Investing.com – Investing.com
By Sam Boughedda
Investing.com — Aridis Pharmaceuticals Inc 's (NASDAQ:) monoclonal antibody cocktail treatment is potentially first-in-class, H.C. Wainwright analyst Vernon Bernardino told investors Wednesday.
Last week Aridis announced that the drug, AR-701, is broadly reactive against Omicron and other Covid-19 variants, SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome Coronavirus), and the common cold, which is a type of human coronavirus.